Category: WFN1 Contributors

12312410 / 1231 POSTS
By David Bautz, PhDNASDAQ:VKTX READ THE FULL VKTX RESEARCH REPORT Business Update Phase 2b VOYAGE Trial Initiated On November 19, 2019, Viking Therapeutics, Inc. (NASDAQ:VKTX) announced that the Phase 2b VOYAGE trial of VK2809 in patients with biopsy ...
By David Bautz, PhDNASDAQ:BTAI READ THE FULL BTAI RESEARCH REPORT Business Update BioXcel Therapeutics, Inc. (NASDAQ:BTAI) is a biopharmaceutical company developing novel therapeutics using EvolverAI, the company’s proprietary research and developmen ...
By David Bautz, PhDNASDAQ:BCLI READ THE FULL BCLI RESEARCH REPORT Business Update Phase 3 ALS Trial is Fully Enrolled On October 10, 2019, BrainStorm Cell Therapeutics, Inc. (NASDAQ:BCLI) announced that the Phase 3 clinical trial of NurOwn® in patien ...
By Brian Marckx, CFANASDAQ:MTBC READ THE FULL MTBC RESEARCH REPORT Q3 2019 Results: MTBC, Inc (NASDAQ:MTBC) reported financial results for their third quarter 2019 and provided a business update. Revenue was down 1% yoy, up 1% qoq and about 6% bette ...
Before I even get into the best way to follow-up with a prospect, I need to be firm about one thing: never start what you can’t finish! Thinking you can make a couple prospecting calls and that’s all it will take is foolish. Similarly, thinking ...
NASDAQ:SNES (Source: Shutterstock) Leptospira is a bacterium that is transmitted by rats to humans. As per CDC, contracting Leptospirosis can cause illness and when left untreated can lead to respiratory distress, kidney damage, liver failure and de ...
By Lisa ThompsonNASDAQ:ABDC READ THE FULL ABDC RESEARCH REPORT Alcentra Capital (NASDAQ:ABDC) reported it Q3 2019, which we expect is its last quarter as a public company. It is in the process of being purchased by Crescent Capital BDC for $11.02 per ...
By David Bautz, PhDOTC:CHEXF READ THE FULL CHEXF RESEARCH REPORT We are initiating coverage of Avivagen, Inc. (OTC:CHEXF) with a valuation of $2.50. Avivagen is developing products to support animal health, which includes replacing antibiotics in liv ...
By Lisa ThompsonNASDAQ:NETE READ THE FULL NETE RESEARCH REPORT Net Element (NASDAQ:NETE) has been fine tuning its business over the past year, focusing on more profitable business and working to eliminate the cash burn and turn it to a positive to av ...
By David Bautz, PhD NASDAQ:CFRXREAD THE FULL CFRX RESEARCH REPORTBusiness Update Phase 3 Clinical Trial to Initiate in 4Q19 On October 2, 2019, ContraFect Corp. (NASDAQ:CFRX) announced that following a successful ‘end-of-Phase 2’ meeting with the FDA ...
12312410 / 1231 POSTS